2-hydroxyimipramine (BioDeep_00000025619)

   

human metabolite Endogenous blood metabolite


代谢物信息卡片


2-[3-(dimethylamino)propyl]-2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-6-ol

化学式: C19H24N2O (296.18885339999997)
中文名称:
谱图信息: 最多检出来源 Homo sapiens(blood) 33.33%

分子结构信息

SMILES: CN(C)CCCN1C2=C(CCC3=CC=CC=C31)C=C(C=C2)O
InChI: InChI=1S/C19H24N2O/c1-20(2)12-5-13-21-18-7-4-3-6-15(18)8-9-16-14-17(22)10-11-19(16)21/h3-4,6-7,10-11,14,22H,5,8-9,12-13H2,1-2H3

描述信息

2-hydroxyimipramine is a metabolite of imipramine. Imipramine (sold as Antideprin, Deprimin, Deprinol, Depsol, Depsonil, Dynaprin, Eupramin, Imipramil, Irmin, Janimine, Melipramin, Surplix, Tofranil), also known as melipramine, is an antidepressant medication, a tricyclic antidepressant of the dibenzazepine group. Imipramine is mainly used in the treatment of major depression and enuresis (inability to control urination). It has also been evaluated for use in panic disorder. (Wikipedia)

同义名列表

3 个代谢物同义名

2-[3-(dimethylamino)propyl]-2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-6-ol; 2-Hydroxyimipramine hydrochloride; 2-Hydroxyimipramine



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

2 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(2)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance. Journal of medicinal chemistry. 2009 Aug; 52(15):4844-52. doi: 10.1021/jm900403j. [PMID: 19445515]
  • R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
  • S Morinobu, T Tanaka, S Kawakatsu, S Totsuka, E Koyama, K Chiba, T Ishizaki, T Kubota. Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy. Psychiatry and clinical neurosciences. 1997 Aug; 51(4):253-7. doi: 10.1111/j.1440-1819.1997.tb02593.x. [PMID: 9316174]
  • A G Chen, Y K Wing, H Chiu, S Lee, C N Chen, K Chan. Simultaneous determination of imipramine, desipramine and their 2- and 10-hydroxylated metabolites in human plasma and urine by high-performance liquid chromatography. Journal of chromatography. B, Biomedical sciences and applications. 1997 May; 693(1):153-8. doi: 10.1016/s0378-4347(97)00053-4. [PMID: 9200529]
  • H Madsen, K K Nielsen, K Brøsen. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study. British journal of clinical pharmacology. 1995 Apr; 39(4):433-9. doi: 10.1111/j.1365-2125.1995.tb04473.x. [PMID: 7640151]
  • D J Hermann, T F Krol, G E Dukes, E K Hussey, M Danis, Y H Han, J R Powell, L J Hak. Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine. Journal of clinical pharmacology. 1992 Feb; 32(2):176-83. doi: 10.1002/j.1552-4604.1992.tb03823.x. [PMID: 1613128]
  • B G Pollock, J M Perel. Imipramine and 2-hydroxyimipramine: comparative cardiotoxicity and pharmacokinetics in swine. Psychopharmacology. 1992; 109(1-2):57-62. doi: 10.1007/bf02245480. [PMID: 1365672]
  • J P Foglia, D Sorisio, J M Perel. Determination of imipramine, desipramine and their hydroxy metabolites by reversed-phase chromatography with ultraviolet and coulometric detection. Journal of chromatography. 1991 Dec; 572(1-2):247-58. doi: 10.1016/0378-4347(91)80489-y. [PMID: 1818058]
  • K Brøsen, T Zeugin, U A Meyer. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clinical pharmacology and therapeutics. 1991 Jun; 49(6):609-17. doi: 10.1038/clpt.1991.77. [PMID: 2060250]
  • R B Dell, K Hein, R Ramakrishnan, J Puig-Antich, T Cooper. Model for the kinetics of imipramine and its metabolites in adolescents. Therapeutic drug monitoring. 1990 Sep; 12(5):450-9. doi: 10.1097/00007691-199009000-00008. [PMID: 2293407]
  • D A Ciraulo, J G Barnhill, J H Jaffe, A M Ciraulo, M F Tarmey. Intravenous pharmacokinetics of 2-hydroxyimipramine in alcoholics and normal controls. Journal of studies on alcohol. 1990 Jul; 51(4):366-72. doi: 10.15288/jsa.1990.51.366. [PMID: 2359311]
  • S H Preskorn, S J Bupp, E B Weller, R A Weller. Plasma levels of imipramine and metabolites in 68 hospitalized children. Journal of the American Academy of Child and Adolescent Psychiatry. 1989 May; 28(3):373-5. doi: 10.1097/00004583-198905000-00011. [PMID: 2738003]
  • A D Fraser, E Susnik, A F Isner. Analysis of 2-hydroxyimipramine in an imipramine-related fatality. Journal of forensic sciences. 1987 Mar; 32(2):543-9. doi: NULL. [PMID: 3572345]
  • K Brøsen, S V Otton, L F Gram. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clinical pharmacology and therapeutics. 1986 Nov; 40(5):543-9. doi: 10.1038/clpt.1986.221. [PMID: 3769385]
  • K Brøsen, R Klysner, L F Gram, S V Otton, P Bech, L Bertilsson. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. European journal of clinical pharmacology. 1986; 30(6):679-84. doi: 10.1007/bf00608215. [PMID: 3533565]
  • K Brøsen, L F Gram, R Klysner, P Bech. Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics. European journal of clinical pharmacology. 1986; 30(1):43-9. doi: 10.1007/bf00614194. [PMID: 3709631]
  • C L DeVane, J W Simpkins. Pharmacokinetics of imipramine and its major metabolites in pregnant rats and their fetuses following a single dose. Drug metabolism and disposition: the biological fate of chemicals. 1985 Jul; 13(4):438-42. doi: NULL. [PMID: 2863107]
  • A I Barkai, R F Suckow, T B Cooper. Imipramine and its metabolites: relationship to cerebral catecholamines in rats in vivo. The Journal of pharmacology and experimental therapeutics. 1984 Aug; 230(2):330-5. doi: NULL. [PMID: 6747838]
  • S A Stout, C L DeVane. Quantification of imipramine and its major metabolites in whole blood, brain, and other tissues of the rat by liquid chromatography. Psychopharmacology. 1984; 84(1):39-41. doi: 10.1007/bf00432021. [PMID: 6436888]
  • C L DeVane, J W Simpkins, S A Stout. Cerebral and blood pharmacokinetics of imipramine and its active metabolites in the pregnant rat. Psychopharmacology. 1984; 84(2):225-30. doi: 10.1007/bf00427450. [PMID: 6438681]
  • T A Sutfin, C L DeVane, W J Jusko. The analysis and disposition of imipramine and its active metabolites in man. Psychopharmacology. 1984; 82(4):310-7. doi: 10.1007/bf00427676. [PMID: 6427820]
  • L F Gram, M Bjerre, P Kragh-Sørensen, B Kvinesdal, J Molin, O L Pedersen, N Reisby. Imipramine metabolites in blood of patients during therapy and after overdose. Clinical pharmacology and therapeutics. 1983 Mar; 33(3):335-42. doi: 10.1038/clpt.1983.42. [PMID: 6825388]
  • W Z Potter, H M Calil, T A Sutfin, A P Zavadil, W J Jusko, J Rapoport, F K Goodwin. Active metabolites of imipramine and desipramine in man. Clinical pharmacology and therapeutics. 1982 Mar; 31(3):393-401. doi: 10.1038/clpt.1982.50. [PMID: 7060321]